A Phase III, 4-week, Randomized, Double-blind Study to Compare 'Closed' Triple Therapy (FF/UMEC/VI), 'Open' Triple Therapy (FF/VI + UMEC) and Dual Therapy (FF/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 25 Jul 2016
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Umeclidinium (Primary) ; Vilanterol/fluticasone furoate (Primary) ; Salbutamol
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 20 Jul 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Jun 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016.
- 16 Jun 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Nov 2016.